Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Width

Sponsor
Duomed (Industry)
Overall Status
Terminated
CT.gov ID
NCT03429374
Collaborator
(none)
16
11
2
30
1.5
0

Study Details

Study Description

Brief Summary

In laparoscopic ventral hernia repair, an abundance of methods has been developed to fix the mesh to the abdominal wall, including sutures (non-absorbable or absorbable), staples (non-absorbable or absorbable), clips, tacks (non-absorbable or absorbable) and (fibrin and synthetic) glues. Which fixation technique is superior, is still under evaluation. There is clearly a need for larger trials to obtain confident results on the safety and performance of glue mesh fixation and tack mesh fixation in LVHR. The hypothesis of this prospective, randomized controlled study is that post-operative pain at 4 to 6 weeks after mesh fixation with glue (LiquiBand® Fix 8™) will not differ compared to treatment with absorbable tacks during LVHR. A total of 510 patients will be recruited for this trial. This study will assess: pain, hernia recurrence, safety, procedural characteristics, technical success, analgesic intake, period to return to normal activity and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Device: Liquiband Fix8
  • Device: Absorbable tack
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients are randomly allocated to group 1 or group 2: Group 1: Mesh fixation with tacks. Group 2: Mesh fixation with glue.Patients are randomly allocated to group 1 or group 2:Group 1: Mesh fixation with tacks. Group 2: Mesh fixation with glue.
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Width: a Multicenter Randomized Controlled Study
Actual Study Start Date :
Nov 19, 2018
Actual Primary Completion Date :
May 20, 2021
Actual Study Completion Date :
May 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Liquiband Fix8 glue mesh fixation

Device: Liquiband Fix8
LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.

Active Comparator: Mesh fixation with absorbable tacks

Device: Absorbable tack
Absorbable tack

Outcome Measures

Primary Outcome Measures

  1. Pain in both groups at 4-6 weeks after LVHR using the Visual Analog Scale (VAS) [At 4 - 6 weeks]

    The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain. The patient is asked to select the number on the scale that corresponds to the worst level of pain he/she experiences. Pain is classified into mild (1 - 30 mm), moderate (31 - 60 mm) and severe (61 - 100 mm). Absence of pain is defined as VAS = 0.

Secondary Outcome Measures

  1. Period of hospitalization [up to 5 days]

    Record the number of days in hospital until discharge

  2. Operating time [Intra-operatively]

  3. Intra-operative adverse events [Intra-operatively]

    Intra-operative adverse events include bleeding and enterotomy

  4. Post-operative adverse events [up to 24 months follow-up]

    Post-operative adverse events include seroma (i.e. accumulation of wound fluid), ileus (i.e. bowel obstruction), infection, bowel injury, major bleeding requiring blood transfusion or re-intervention, complications due to anesthesia and minor bleeding at a trocar insertion site

  5. Usability of the glue during the index-procedure [Intra-operatively]

    Usability scoring: 1 = bad -> 3 = moderate -> 5 = excellent

  6. Technical success of glue fixation [Intra-operatively]

    During the index-procedure, the investigator will register whether fixation of the mesh with glue achieved technical success or not. Technical success is defined as successful hernia repair as intended.

  7. Technical success of tack fixation [Intra-operatively]

    During the index-procedure, the investigator will register whether fixation of the mesh with tacks achieved technical success or not. Technical success is defined as successful hernia repair as intended.

  8. Pain at baseline using the VAS scale [At baseline]

    The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain.

  9. Pain at discharge using the VAS scale [Up to 5 days]

    The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain.

  10. Pain at 12 months follow-up using the VAS scale [At 12 months follow-up]

    The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain.

  11. Pain at 24 months follow-up using the VAS scale [At 24 months follow-up]

    The VAS scale contains a 0 - 100 grading with 0 equaling no pain and 100 equaling the worst conceivable pain.

  12. Postoperative analgesic intake [Up to 24 months follow-up]

    Period of intake

  13. Postoperative analgesic intake [Up to 24 months follow-up]

    Type of intake

  14. Period to return to normal activity [At 4 - 6 weeks follow-up]

    Number of days after the index-procedure at which the patient resumes normal activities.

  15. Quality of life at baseline. [At baseline]

    The Carolinas Comfort Scale questionnaire is a validated, disease-specific, quality of life questionnaire developed for patients undergoing hernia repair with mesh. It is a 23-item questionnaire that measures severity of pain, sensation, and movement limitations from the mesh in eight categories. The CCS score is derived by adding the scores from each of the 23 items. The best possible score is 0 and the worst possible score is 115.

  16. Quality of life at 4-6 weeks. [At 4 - 6 weeks follow-up]

    CCS questionnaire

  17. Quality of life at 12 months follow-up. [At 12 months follow-up]

    CCS questionnaire

  18. Quality of life at 24 months follow-up. [At 24 months follow-up]

    CCS questionnaire

  19. Recurrences during follow-up [up to 24 months follow-up]

    A clinical examination is conducted to evaluate recurrence. If there is any suspicion of recurrence, an ultrasound or MRI is performed according to hospital practice to distinguish true recurrences from bulging.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patient with ventral hernia (primary or incisional) with a defect size between 2 and 5 cm and eligible for laparoscopic repair.

  2. Patients with ASA grade I to III.

  3. Patient is at least 18 years old.

  4. Patient must sign and date the informed consent form prior to treatment.

Exclusion Criteria:
  1. Patient with a recurrence of a previously treated ventral hernia repaired with mesh. Recurrences are only allowed to be included after former primary (suture) repair or retromuscular/onlay mesh repair.

  2. Patient is treated by open surgery.

  3. Patient has more than one defect. Treatment of Swiss-cheese defects (multiple small defects) is allowed if all defects can be treated with one mesh. Total width cannot exceed 5 cm.

  4. Patient with a complex hernia, likely not eligible for laparoscopic repair. Complexity is determined by the investigator (adhesions, small bowel resection, etc).

  5. Patient with a life expectancy of less than 2 years.

  6. Patient is suspected of being unable to comply with the study protocol.

  7. Patient with severe chronic obstructive pulmonary disease.

  8. Patient with ASA IV or V.

  9. Patient is pregnant.

  10. Patient needs acute surgery.

  11. Patient is scheduled for surgery within 6 weeks after the index-procedure.

  12. Patient has fibromyalgia.

  13. Patient with depression as shown in patient medical record.

  14. Patient is enrolled in another study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Network Antwerp (ZNA) Jan Palfijn Antwerp Belgium
2 General Hospital Sint Jan Brugge Brugge Belgium
3 University Hospital Brussels Brussels Belgium
4 CHU Charleroi Charleroi Belgium
5 General Hospital Sint Vincentius Deinze Deinze Belgium
6 ZOL Genk Genk Belgium
7 University Hospital Leuven Leuven Belgium
8 CHR Namur Namur Belgium
9 General Hospital Nikolaas Sint-Niklaas Belgium
10 Regional Hospital HH Tienen Tienen Belgium
11 General Hospital Delta Torhout Torhout Belgium

Sponsors and Collaborators

  • Duomed

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duomed
ClinicalTrials.gov Identifier:
NCT03429374
Other Study ID Numbers:
  • BLITS-01
First Posted:
Feb 12, 2018
Last Update Posted:
May 24, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2021